Skip to main content
SpringerLink
Log in

Germ Cell Tumors of the Testis

  • Educational Review
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Testicular cancer is the most common malignancy in men aged 20 to 35 years and accounts for approximately 1% of all male malignancies. Through the appropriate utilization of clinical trials, effective treatment paradigms have been developed for the management of all stages of testicular cancer. The multidisciplinary approach to the management of germ cell tumors of the testis has resulted in survival rates of > 90% overall. This review summarizes the principal management of germ cell tumors of the testis, highlighting the indications for surgery, controversies surrounding the integration of surgery, and alternative management strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society, 2005

    Google Scholar 

  2. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170:5–11

    Article  Google Scholar 

  3. McKiernan J, Goluboff E, Liberson G, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 1999;162:361–3

    Article  Google Scholar 

  4. Daniels J, Stutzman R, McLeod D. A comparison of testicular tumors in black and white patients. J Urol 1981;125:341–2

    Google Scholar 

  5. Bosl G, Bajorin D, Sheinfeld J, Motzer R, Chaganti R. Cancer of the testis. In: Devita Y, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 2000:1491–518

    Google Scholar 

  6. Moul J, Paulson D, Dodge R, Walther P. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 1990;143:520–3

    Google Scholar 

  7. Bosl G, Goldman A, Lange P, Vogelzang N, Fraley E, Levitt S. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981;2:970–3

    Article  Google Scholar 

  8. Moul J, Moellman J. Unnecessary mastectomy for gynecomastia in a testicular cancer patient. Mil Med 1992;157:433–4

    Google Scholar 

  9. Stephenson AJ, Russo P, Kaplinsky R, Sheinfeld J. Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. J Urol 2004;171:1474–7

    Article  Google Scholar 

  10. Bochner BH, Lerner SP, Kawachi M, Williams RD, Scardino PT, Skinner DG. Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? Urology 1995;46:408–11

    Article  Google Scholar 

  11. Capelouto C, Clark P, Ransil B, Loughlin K. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995;153:1397–401

    Google Scholar 

  12. Van der Schyff S, Heidenreich A, Weifbach L. Organ preserving surgery in testicular cancer: long term results (abstract). J Urol 2000;163:645A

    Google Scholar 

  13. Leibovitch I, Foster R, Kopecky K, Donohue J. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759–63

    Article  Google Scholar 

  14. Hilton S, Herr H, Teitcher J, Begg C, Castellino R. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997;169:521–5

    Google Scholar 

  15. Fleming I, ed. AJCC Cancer Staging Handbook. Philadelphia: Lippincott-Raven, 1998

    Google Scholar 

  16. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594–603

    Google Scholar 

  17. Jamieson J, Dobsin J. Lymphatics of the testicle. Lancet 1910;493–5.

    Article  Google Scholar 

  18. Skinner D, Leadbetter W. The surgical management of testis tumors. J Urol 1971;106:84–93

    Google Scholar 

  19. Donohue J, Zachary J, Maynard B. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128:315–20

    Google Scholar 

  20. Weiscbach L, Boedefeld E. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as a basis for a modified staging lymph node dissection in stage I. J Urol 1987;138:77–82

    Google Scholar 

  21. Sogani P. Evolution of the management of stage I nonseminomatous germ cell tumors of the testis. Urol Clin North Am 1991;18:561–73

    Google Scholar 

  22. Fossa S, Horwich A, Russell J, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146–54

    Google Scholar 

  23. Fossa S, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long term post irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383–8

    Google Scholar 

  24. Dosmann M, Zagars G. Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 1993;26:382–90

    Google Scholar 

  25. Willan B, McGowan D. Seminoma of the testis: a 22 year experience with radiotherapy. Int J Radiat Oncol Biol Phys 1985;11:1769–75

    Google Scholar 

  26. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255–62

    Google Scholar 

  27. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931–4.

    Google Scholar 

  28. Loehrer P, Birch R, Williams S, Greco A, Einhorn L. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987;5:1212–20

    Google Scholar 

  29. Lashley D, Lowe B. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25:405–23

    Article  Google Scholar 

  30. Pohar K, Rabbani F, Bosl G, Motzer R, Bajorin D, Sheinfeld J. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 2003;170:1155–8

    Article  Google Scholar 

  31. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855–8

    Article  Google Scholar 

  32. Jewett M, Kong Y, Goldberg S, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988;139:1220–3

    Google Scholar 

  33. Baniel J, Foster R, Rowland R, Bihrle R, Donohue J. Complications of primary retroperitoneal lymph node dissection. J Urol 1994;152:424–7

    Google Scholar 

  34. Hartlapp J, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl 1987;10:277–84

    Google Scholar 

  35. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991;9:1393–6

    Google Scholar 

  36. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993;149:237–43

    Google Scholar 

  37. Rabbani F, Sheinfeld J, Mohseni HF, Leon A, Rentzepis MJ, Reuter VE. Low volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:2020–5

    Google Scholar 

  38. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433–8

    Google Scholar 

  39. Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464–7

    Article  Google Scholar 

  40. Gerber GS, Bissada NK, Hulbert JC, Kavoussi LR, Moore RG, Kantoff PW. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J Urol 1994;152:1188–92

    Google Scholar 

  41. Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J Urol 1996;156:1108–13

    Article  Google Scholar 

  42. Janetschek G, Hobisch A, Holtl L, Bartsch G. Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve. J Urol 1996;156:89–93

    Article  Google Scholar 

  43. Nelson JB, Chen RN, Bishoff JT, Oh WK, Kantoff PW, Donehower RC. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999;54:1064–7

    Article  Google Scholar 

  44. LeBlanc E, Caty A, Dargent D, Querleu D, Mazeman E. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001;165:89–92

    Article  Google Scholar 

  45. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003;62:324–7

    Article  Google Scholar 

  46. Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch G. Long-term result of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 2004;63:550–5

    Article  Google Scholar 

  47. Castillo OA, Urena RD, Pinto IF. Laparoscopic retroperitoneal lymph node dissection for stage I, II NSGCT: 10 years experience (abstract). J Urol 2004;171:933A.

    Google Scholar 

  48. Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37:251–60

    Article  Google Scholar 

  49. Oliver RT, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 1992;148:1453–5

    Google Scholar 

  50. Cullen M, Stenning S, Parkinson M. Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis (NSGCTT): an MRC (UK) study report (abstract). Proc Am Soc Clin Oncol 1995;14:244

    Google Scholar 

  51. Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor. J Urol 2000;163:1785–7

    Article  Google Scholar 

  52. Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725–32

    Google Scholar 

  53. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–23

    Article  Google Scholar 

  54. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23:2781–8

    Article  Google Scholar 

  55. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163–72

    Google Scholar 

  56. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988;6:1031–40

    Google Scholar 

  57. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692–701

    Google Scholar 

  58. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683–94

    Google Scholar 

  59. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177–87

    Google Scholar 

  60. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818–26

    Google Scholar 

  61. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569–73

    Google Scholar 

  62. Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 1998;16:65–71

    Google Scholar 

  63. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275–80

    Google Scholar 

  64. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993;11:1294–9

    Google Scholar 

  65. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an international study group. J Clin Oncol 2001;19:2647–57

    Google Scholar 

  66. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176–9

    Google Scholar 

  67. Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997;15:1455–64

    Google Scholar 

  68. Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989;141:557–9

    Google Scholar 

  69. Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998;159:133–8

    Google Scholar 

  70. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170–6

    Google Scholar 

  71. Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol 1995;154:1370–2

    Article  Google Scholar 

  72. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43:74–80

    Article  Google Scholar 

  73. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11:324–9

    Google Scholar 

  74. Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 2004;171:168–71

    Article  Google Scholar 

  75. Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860–2

    Article  Google Scholar 

  76. De Santis M, Becherer A, Bokemeyer C, et al. 2-18Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034–9

    Article  Google Scholar 

  77. Moshorafa AA, Foster RS, Koch MO. Complications of post-chemotherapy retroperitoneal lymph node dissection (abstract). J Urol 2003;169:930A

    Google Scholar 

  78. Patel MI, Beck S, Bosl GJ, Sheinfeld J. Histology of good risk nonseminomatous germ cell tumor (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after 4 cycles of etoposide and cisplatin (EPx4) (abstract). J Urol 2003;169:681A

    Google Scholar 

  79. See WA, Laurenzo JF, Dreicer R, Hoffman HT. Incidence and management of testicular carcinoma metastatic to the neck. J Urol 1996;55:590–2

    Article  Google Scholar 

  80. Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 1986;57:978–83

    Google Scholar 

  81. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified. Chest 1997;112:967–73

    Google Scholar 

  82. Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996;14:1765–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, 10021

    Brett S. Carver MD & Joel Sheinfeld MD

Authors
  1. Brett S. Carver MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel Sheinfeld MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Sheinfeld MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carver, B.S., Sheinfeld, J. Germ Cell Tumors of the Testis. Ann Surg Oncol 12, 871–880 (2005). https://doi.org/10.1245/ASO.2005.01.013

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2005.01.013

Keywords

Search

Navigation